```html

Zollinger‑Ellison Syndrome (Gastrin Hypersecretion)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors, called gastrin‑producing neuroendocrine tumors (gastrinomas), develop in the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates stomach acid production. The resulting hyperacidity can cause severe peptic ulcers, diarrhea, and malabsorption.

Although ZES accounts for less than 1 % of all peptic ulcer disease, it is clinically important because the ulcers are often refractory to standard therapy and because the gastrinomas can be malignant.

• Incidence: Approximately 0.5–2 cases per million people per year.
• Prevalence: Estimated 2–5 cases per 100,000 individuals worldwide.
• Age and gender: Most commonly diagnosed between ages 30–60; slight male predominance (≈60 % men).
• Genetic link: About 25 % of cases occur as part of multiple endocrine neoplasia type 1 (MEN‑1), an inherited syndrome.

Symptoms

The clinical picture is dominated by the effects of excess gastric acid and the mass effect of the tumor. Symptoms can be intermittent early on and become progressively severe.

Gastrointestinal symptoms

• Refractory peptic ulcer disease: Ulcers that do not heal with standard proton‑pump inhibitor (PPI) therapy; may occur in unusual locations (jejunum, ileum).
• Abdominal pain: Burning or gnawing pain, often worsening 1–2 hours after meals.
• Diarrhea: Frequent, watery stools; may be oily if fat malabsorption occurs.
• Steatorrhea: Foul‑smelling, fatty stools due to pancreatic enzyme inactivation by acid.
• Nausea & vomiting: Particularly after large meals.

Systemic symptoms

• Weight loss: From malabsorption and chronic diarrhea.
• Fatigue & anemia: Chronic blood loss from ulcerations.
• Heartburn & acid reflux: Due to high acid load.

Signs related to tumor location

• Pancreatic mass: May cause jaundice, back pain, or a palpable abdominal mass.
• Duodenal mass: May present with obstruction or bleeding.

Causes and Risk Factors

ZES is fundamentally a disease of gastrin‑producing neuroendocrine cells.

Primary causes

• Gastrinomas: Typically arise in the duodenum (≈70 %) or pancreas (≈25 %).
• MEN‑1 syndrome: Germline mutations in the MEN1 tumor suppressor gene increase the risk of gastrinomas as well as parathyroid, pituitary, and other neuroendocrine tumors.

Risk factors

• Family history of MEN‑1 or known MEN1 mutation.
• Previous diagnosis of other neuroendocrine tumors.
• Chronic proton‑pump inhibitor use does not cause ZES, but may mask symptoms, leading to delayed diagnosis.

Diagnosis

Because the condition is rare and symptoms overlap with common ulcer disease, a high index of suspicion is needed.

Initial laboratory evaluation

• Fasting serum gastrin level: Levels >1000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially if gastric pH <2.0.
• Secretin stimulation test: Administration of secretin paradoxically raises gastrin in ZES (≥120 pg/mL rise) – a sensitive and specific confirmatory test (Jonk et al., 2020).
• Gastric pH measurement: pH <2 confirms acid hypersecretion.

Imaging studies

• Somatostatin receptor scintigraphy (SRS) / Octreoscan: Detects tumors expressing somatostatin receptors.
• 68Ga‑DOTATATE PET/CT: Superior sensitivity for small neuroendocrine tumors.
• Endoscopic ultrasound (EUS): Helpful for locating small pancreatic lesions.
• Contrast‑enhanced CT or MRI: Provides anatomic details and assesses metastasis (especially to liver and lymph nodes).

Endoscopic evaluation

Upper endoscopy (EGD) can visualize ulcerations and may allow biopsy of suspected duodenal lesions, but gastrinomas themselves are usually submucosal and not seen endoscopically.

Genetic testing

Patients with a personal or family history suggestive of MEN‑1 should undergo germline MEN1 mutation analysis. Identification guides screening for other endocrine tumors.

Treatment Options

Therapy aims to control acid hypersecretion, remove or shrink the tumor, and monitor for recurrence.

Medical management

• High‑dose proton‑pump inhibitors (PPIs): Omeprazole 60–120 mg/day, pantoprazole 80–120 mg/day, or equivalent. PPIs are the cornerstone, normalizing gastric pH and allowing ulcer healing in 80–90 % of patients (Mayo Clinic).
• H2‑receptor antagonists: Less effective than PPIs but may be added for breakthrough symptoms.
• Octreotide or Lanreotide (somatostatin analogs): Reduce gastrin secretion and can shrink tumors; useful when surgery is not feasible.
• Immunotherapy / targeted agents: Everolimus and sunitinib have shown activity in metastatic neuroendocrine tumors, though data specific to gastrinomas are limited.

Surgical treatment

• Curative resection: Preferred for localized gastrinomas. Enucleation or pancreaticoduodenectomy (Whipple) may be performed depending on size/location.
• Debulking surgery: For metastatic disease, removing >90 % of tumor burden can improve symptom control and PPI dose requirements.
• Liver-directed therapies: Radiofrequency ablation or hepatic artery embolization for liver metastases.

Other interventional options

• Endoscopic tumor ablation: Emerging technique for very small duodenal gastrinomas.
• Peptide receptor radionuclide therapy (PRRT): Uses radiolabeled somatostatin analogs (e.g., ^177Lu‑DOTATATE) for metastatic disease with good response rates.

Lifestyle and supportive care

• Small, frequent meals to reduce acid load.
• Avoidance of alcohol, caffeine, nicotine, and NSAIDs, which increase acid secretion.
• Calcium and vitamin D supplementation if malabsorption leads to deficiency.
• Regular bone density monitoring because chronic acid hypersecretion can affect calcium balance.

Living with Zollinger‑Ellison Syndrome (gastrin hypersecretion)

Long‑term management blends medication adherence, monitoring, and lifestyle tweaks.

Daily medication routine

• Take PPIs 30–60 minutes before the first meal of the day; split dosing may be needed for very high acid output.
• Carry a rescue dose (e.g., famotidine 20 mg) for breakthrough symptoms.
• Keep a medication log and schedule regular pharmacy refills to avoid gaps.

Nutrition tips

• Consume a diet low in fat and high in complex carbohydrates.
• Include probiotic‑rich foods (yogurt, kefir) to support gut mucosa.
• Stay hydrated—diarrhea can cause electrolyte loss; replace with oral rehydration solutions if needed.

Monitoring schedule

• Every 3–6 months: Serum gastrin level, liver function tests, and CBC.
• Annually: Imaging (CT/MRI or DOTATATE PET) to assess tumor status.
• For MEN‑1 patients: Annual screening for parathyroid, pituitary, and other pancreatic neuroendocrine tumors.

Psychosocial aspects

Living with a rare chronic disease can be stressful. Consider:

• Joining support groups (e.g., Neuroendocrine Cancer Patient Foundation).
• Seeking counseling or psychotherapy for anxiety/depression.
• Keeping a symptom diary to discuss trends with your healthcare team.

Prevention

Because ZES is largely driven by sporadic mutations or inherited MEN‑1, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling: For families with known MEN‑1 mutations; cascade testing can identify at‑risk relatives early.
• Avoid chronic irritation: Long‑term use of NSAIDs or heavy alcohol intake may exacerbate ulcer disease, prompting earlier detection of underlying gastrinomas.
• Regular medical check‑ups: For individuals with MEN‑1, routine endocrine screening helps catch gastrinomas before they become symptomatic.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated peptic ulcer – a surgical emergency.
• Gastrointestinal bleeding – may require endoscopic or operative intervention.
• Severe malabsorption – leading to weight loss, anemia, osteoporosis, and electrolyte disturbances.
• Metastatic disease – 60–90 % of gastrinomas are malignant; common sites include liver, lymph nodes, and bone.
• Refractory diarrhea – can cause dehydration and renal insufficiency.
• Secondary infections – chronic acid suppression may increase susceptibility to Clostridioides difficile.

When to Seek Emergency Care

---

Information compiled from peer‑reviewed journals and reputable health organizations including the Mayo Clinic, Cleveland Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the World Health Organization (WHO). This guide is for educational purposes and does not replace personalized medical advice.

```